| Allegheny Endocrinology Associates, Pc | |
|
420 E North Avenue Suite 205 Pittsburgh PA 15212 | |
| (412) 359-3426 | |
| (412) 359-6974 |
| Full Name | Allegheny Endocrinology Associates, Pc |
|---|---|
| Speciality | Internal Medicine |
| Location | 420 E North Avenue, Pittsburgh, Pennsylvania |
| Authorized Official Name and Position | Hemlata Moturi (OWNER/PHYSICIAN) |
| Authorized Official Contact | 4123593426 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Allegheny Endocrinology Associates, Pc 420 E North Avenue Suite 205 Pittsburgh PA 15212 Ph: (412) 359-3426 | Allegheny Endocrinology Associates, Pc 420 E North Avenue Suite 205 Pittsburgh PA 15212 Ph: (412) 359-3426 |
| NPI Number | 1003962895 |
|---|---|
| Provider Enumeration Date | 01/26/2007 |
| Last Update Date | 09/07/2022 |
| Medicare PECOS PAC ID | 3779558457 |
|---|---|
| Medicare Enrollment ID | O20040826001020 |
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.
A study published today in the prestigious New England Journal of Medicine offers the most in-depth assessment yet of the safety and effectiveness of a high-tech alternative to brain surgery to treat the uncontrollable shaking caused by the most common movement disorder.
Montreux Equity Partners, LLC, and GC Aesthetics, Ltd., today announced the completion of a US$30 million private equity investment by Montreux into GCAL. GCAL is a leading designer, manufacturer, and distributor of medical devices for the global aesthetics industry. Montreux entered into the financing agreement with GCAL to accelerate the company's expansion plans.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003962895 | NPI | - | NPPES |
| 1331284 | Other | PA | BLUE SHIELD |
| 123010 | Other | PA | UNISON / MEDPLUS |
| 103913 | Other | PA | UPMC |
| 2142173 | Other | PA | UNITED HEALTHCARE |
| 2654905 | Other | PA | AETNA |
| CJ3214 | Other | PA | RAILROAD MEDICARE |
| 0018695400001 | Medicaid | PA | |
| 212797 | Other | PA | HEALTH AMERICA |
| 1002654 | Other | PA | GATEWAY HEALTH PLAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | (* (Not Available)) | Primary |
| Provider Name | Murray B Gordon |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1366414468 PECOS PAC ID: 8921164930 Enrollment ID: I20110104001124 |
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.
A study published today in the prestigious New England Journal of Medicine offers the most in-depth assessment yet of the safety and effectiveness of a high-tech alternative to brain surgery to treat the uncontrollable shaking caused by the most common movement disorder.
Montreux Equity Partners, LLC, and GC Aesthetics, Ltd., today announced the completion of a US$30 million private equity investment by Montreux into GCAL. GCAL is a leading designer, manufacturer, and distributor of medical devices for the global aesthetics industry. Montreux entered into the financing agreement with GCAL to accelerate the company's expansion plans.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
› Verified 8 days ago
| Provider Name | Hemlata Moturi |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1053383224 PECOS PAC ID: 9830255835 Enrollment ID: I20110105000769 |
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.
A study published today in the prestigious New England Journal of Medicine offers the most in-depth assessment yet of the safety and effectiveness of a high-tech alternative to brain surgery to treat the uncontrollable shaking caused by the most common movement disorder.
Montreux Equity Partners, LLC, and GC Aesthetics, Ltd., today announced the completion of a US$30 million private equity investment by Montreux into GCAL. GCAL is a leading designer, manufacturer, and distributor of medical devices for the global aesthetics industry. Montreux entered into the financing agreement with GCAL to accelerate the company's expansion plans.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
› Verified 8 days ago
| Provider Name | Patricia Mareda |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497726046 PECOS PAC ID: 6305024993 Enrollment ID: I20110630000198 |
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.
A study published today in the prestigious New England Journal of Medicine offers the most in-depth assessment yet of the safety and effectiveness of a high-tech alternative to brain surgery to treat the uncontrollable shaking caused by the most common movement disorder.
Montreux Equity Partners, LLC, and GC Aesthetics, Ltd., today announced the completion of a US$30 million private equity investment by Montreux into GCAL. GCAL is a leading designer, manufacturer, and distributor of medical devices for the global aesthetics industry. Montreux entered into the financing agreement with GCAL to accelerate the company's expansion plans.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
› Verified 8 days ago
| Provider Name | Jenna D Federoff |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629460050 PECOS PAC ID: 7517245459 Enrollment ID: I20161028000324 |
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.
A study published today in the prestigious New England Journal of Medicine offers the most in-depth assessment yet of the safety and effectiveness of a high-tech alternative to brain surgery to treat the uncontrollable shaking caused by the most common movement disorder.
Montreux Equity Partners, LLC, and GC Aesthetics, Ltd., today announced the completion of a US$30 million private equity investment by Montreux into GCAL. GCAL is a leading designer, manufacturer, and distributor of medical devices for the global aesthetics industry. Montreux entered into the financing agreement with GCAL to accelerate the company's expansion plans.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
› Verified 8 days ago
News Archive
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Zogenix, Inc. today announced completion of enrollment in its open-label Phase 3 safety study (Study 802) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.
A study published today in the prestigious New England Journal of Medicine offers the most in-depth assessment yet of the safety and effectiveness of a high-tech alternative to brain surgery to treat the uncontrollable shaking caused by the most common movement disorder.
Montreux Equity Partners, LLC, and GC Aesthetics, Ltd., today announced the completion of a US$30 million private equity investment by Montreux into GCAL. GCAL is a leading designer, manufacturer, and distributor of medical devices for the global aesthetics industry. Montreux entered into the financing agreement with GCAL to accelerate the company's expansion plans.
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.
› Verified 8 days ago
Heritage Valley Multispecialty Group, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2201 Park Manor Blvd, Pittsburgh, PA 15205 Phone: 412-749-6920 Fax: 412-749-6779 | |
St. Clair Medical Services, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1000 Bower Hill Road, St Clair Hospital - Affiliate Billing - Pamalyn, Pittsburgh, PA 15243 Phone: 412-942-2548 | |
Pittsburgh Family Practice Assoc., Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1517 Forbes Ave, Pittsburgh, PA 15219 Phone: 412-232-3555 Fax: 412-232-3523 | |
West End Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 415 Neptune St, Pittsburgh, PA 15220 Phone: 412-921-7200 Fax: 412-921-4681 | |
Donna L. Knupp Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4381 Murray Ave, Pittsburgh, PA 15217 Phone: 412-521-2857 Fax: 412-521-4918 | |
University Of Pittsburgh Physicians Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5215 Centre Ave, First Floor, Pittsburgh, PA 15232 Phone: 412-647-3087 Fax: 412-647-4050 |